- Home
- SRV vs XFOR Comparison
SRV vs XFOR Comparison
Compare SRV & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- XFOR
- Stock Information
- Founded
- SRV 2007
- XFOR 2014
- Country
- SRV United States
- XFOR United States
- Employees
- SRV N/A
- XFOR N/A
- Industry
- SRV Finance Companies
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRV Finance
- XFOR Health Care
- Exchange
- SRV Nasdaq
- XFOR Nasdaq
- Market Cap
- SRV 125.6M
- XFOR 118.4M
- IPO Year
- SRV N/A
- XFOR N/A
- Fundamental
- Price
- SRV $45.50
- XFOR $0.51
- Analyst Decision
- SRV
- XFOR Buy
- Analyst Count
- SRV 0
- XFOR 3
- Target Price
- SRV N/A
- XFOR $3.67
- AVG Volume (30 Days)
- SRV 33.9K
- XFOR 1.1M
- Earning Date
- SRV 01-01-0001
- XFOR 11-07-2024
- Dividend Yield
- SRV 13.38%
- XFOR N/A
- EPS Growth
- SRV N/A
- XFOR N/A
- EPS
- SRV N/A
- XFOR 0.09
- Revenue
- SRV N/A
- XFOR $563,000.00
- Revenue This Year
- SRV N/A
- XFOR N/A
- Revenue Next Year
- SRV N/A
- XFOR $596.79
- P/E Ratio
- SRV N/A
- XFOR $5.93
- Revenue Growth
- SRV N/A
- XFOR N/A
- 52 Week Low
- SRV $30.73
- XFOR $0.47
- 52 Week High
- SRV $44.30
- XFOR $1.60
- Technical
- Relative Strength Index (RSI)
- SRV 56.89
- XFOR 29.39
- Support Level
- SRV $45.52
- XFOR $0.47
- Resistance Level
- SRV $47.34
- XFOR $0.56
- Average True Range (ATR)
- SRV 0.76
- XFOR 0.05
- MACD
- SRV 0.10
- XFOR -0.01
- Stochastic Oscillator
- SRV 50.93
- XFOR 15.39
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.